A comprehensive review of the therapeutic potential of curcumin nanoformulations.
Phytother Res
; 35(10): 5527-5563, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1479440
ABSTRACT
Today, due to the prevalence of various diseases such as the novel coronavirus (SARS-CoV-2), diabetes, central nervous system diseases, cancer, cardiovascular disorders, and so on, extensive studies have been conducted on therapeutic properties of natural and synthetic agents. A literature review on herbal medicine and commercial products in the global market showed that curcumin (Cur) has many therapeutic benefits compared to other natural ingredients. Despite the unique properties of Cur, its use in clinical trials is very limited. The poor biopharmaceutical properties of Cur such as short half-life in plasma, low bioavailability, poor absorption, rapid metabolism, very low solubility (at acidic and physiological pH), and the chemical instability in body fluids are major concerns associated with the clinical applications of Cur. Recently, nanoformulations are emerging as approaches to develop and improve the therapeutic efficacy of various drugs. Many studies have shown that Cur nanoformulations have tremendous therapeutic potential against various diseases such as SARS-CoV-2, cancer, inflammatory, osteoporosis, and so on. These nanoformulations can inhibit many diseases through several cellular and molecular mechanisms. However, successful long-term clinical results are required to confirm their safety and clinical efficacy. The present review aims to update and explain the therapeutic potential of Cur nanoformulations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Curcumin
/
Nanoparticles
/
COVID-19
/
Neoplasms
Type of study:
Observational study
/
Prognostic study
/
Reviews
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
Phytother Res
Journal subject:
Complementary Therapies
Year:
2021
Document Type:
Article
Affiliation country:
Ptr.7190
Similar
MEDLINE
...
LILACS
LIS